Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: A national multicentre randomised trial

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 121, Issue 4, 2014, Pages 477-486

  Orbo A ^a,b   Vereide, A B ^a   Arnes, M ^b   Pettersen, I ^a   Straume, B ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Endometrial hyperplasia; levonorgestrel impregnated intrauterine device versus oral progestin; therapy

Indexed keywords

ENDOMETRIAL HYPERPLASIA; LEVONORGESTREL-IMPREGNATED INTRAUTERINE DEVICE VERSUS ORAL PROGESTIN; THERAPY;

ADMINISTRATION, ORAL; ADULT; AGED; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL HYPERPLASIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEDROXYPROGESTERONE; MIDDLE AGED; NORWAY; PROGESTINS; RISK; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84894285905     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12499     Document Type: Article

References (43)

1. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J,. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 2004; 14: 348-53.
2. Norwegian Cancer Registry. Annual report. Oslo: Norwegian Cancer Registry, 2009.
3. Kurman RJ, Kaminski PF, Norris HJ,. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56: 403-12.
4. Ferenczy A, Gelfand M,. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160: 126-31.
5. Lindahl B, Alm P, Ferno M, Norgren A,. Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment. Anticancer Res 1990; 10: 725-30.
6. Lindahl B, Willen R,. Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia. Anticancer Res 1998; 18: 3793-5.
7. Randall TC, Kurman RJ,. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90: 434-40.
8. Wheeler DT, Bristow RE, Kurman RJ,. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007; 31: 98898.
9. Reed SD, Voigt LF, Newton KM, Garcia RH, Allison HK, Epplein M, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009; 113: 655-62.
10. 2+ through a tyrosil phosphorylation-independent conformational modification in major vault protein. Cancer Res 2006; 66: 11677-82.
11. Kaku T, Kamura T, Hirakawa T, Sakai K, Amada S, Kobayashi H, et al. Endometrial carcinoma associated with hyperplasia-immunohistochemical study of angiogenesis and p53 expression. Gynecol Oncol 1999; 72: 51-5.
12. Jobo T, Kawaguchi M, Imai M, Kuramoto H,. Treatment for complex atypical hyperplasia of the endometrium. Eur J Gynaecol Oncol 2001; 22: 365-8.
13. Jarvela IY, Santala M,. Treatment of non-atypic endometrial hyperplasia using thermal balloon endometrial ablation therapy. Gynecol Obstet Invest 2005; 59: 202-6.
14. Clark TJ, Neelakantan D, Gupta JK,. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006; 125: 259-64.
15. Bese T, Vural A, Ozturk M, Dagistanli F, Demirkiran F, Tuncdemir M, et al. The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer 2006; 16: 809-13.
16. Andersson JK, Rybo G,. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 690-4.
17. Luukkainen T, Allonen H, Haukkamaa M, Holma P, Pyorala T, Terho J, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception 1987; 36: 169-79.
18. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T,. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982; 17: 529-36.
19. Perino A, Quartararo P, Catinella E, Genova G, Cittadini E,. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 1987; 18: 137-40.
20. Rose G, Edmonds D,. Levonorgestrel IUS-treatment for endometrial cystic hyperplasia. Gynecol Case reports 1997; 104: 614-6.
21. Scarselli G, Tantini C, Colafranceschi M, Taddei GL, Bargelli G, Venturini N, et al. Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol 1988; 9: 284-6.
22. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008; 139: 169-75.
23. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A,. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003; 91: 526-33.
24. Wildemeersch D, Janssens D, Pylyser K, De WN, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007; 57: 210-3.
25. Buttini MJ, Jordan SJ, Webb PM,. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust N Z J Obstet Gynaecol 2009; 49: 316-22.
26. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK,. Oral progestogens v levonorges-trel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203: e1-10.
27. Schulz KF, Altman DG, Moher D,. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8: 18.
28. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK,. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 2013; 28: 1231-6.
29. Orbo A, Baak JP,. Computer-based morphometric image analysis of endometrial hyperplasia. Tidsskr Nor Laegeforen 2000; 120: 496-9.
30. Orbo A, Baak JP, Kleivan I, Lysne S, Prytz PS, Broeckaert MA, et al. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol 2000; 53: 697-703.
31. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K,. Treatment results of endometrial hyperplasia after prospective D-score classification A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008; 111: 68-73.
32. Orbo A, Kaino T, Arnes M, Larsen K, Pettersen I, Moe B,. Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction. Acta Obstet Gynecol Scand 2009; 88: 1234-42.
33. Baak JP, Nauta JJ, Wisse-Brekelmans EC, Bezemer PD,. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone. J Pathol 1988; 154: 335-41.
34. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106: 804-11.
35. Baak JP, Wisse-Brekelmans EC, Fleege JC, van der Putten HW, Bezemer PD,. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract 1992; 188: 856-9.
36. Bergeron C, Nogales FF, Masseroli M, Abeler V, Duvillard P, Muller-Holzner E, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999; 23: 1102-8.
37. Dunton CJ, Baak JP, Palazzo JP, van Diest PJ, McHugh M, Widra EA,. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol 1996; 174: 1518-21.
38. Baak JP, Orbo A, van Diest PJ, Jiwa M, de Bruin P, Broeckaert M, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001; 25: 930-5.
39. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005; 103: 2304-12.
40. Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC,. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190: 462-9.
41. Gunderson CC, Fader AN, Carson KA, Bristow RE,. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-82.
42. Witkiewicz AK, McConnell T, Potoczek M, Emmons RV, Kurman RJ,. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Hum Pathol 2010; 41: 26-32.
43. Tjalma W, Van ME, Weyler J, Dirix L, Van DA, Goovaerts G, et al. Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer. Br J Cancer 1998; 78: 170-4.